Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb

Hermann Einsele • 11 Jun 2022
EHA 2022
Multiple Myeloma Antibodies Elranatamab Teclistamab

Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, comments on the efficacy and toxicity profile of bispecific antibodies for multiple myeloma including teclistamab and elranatamab, discussing overall response rates (ORR), cytokine release syndrome (CRS) and infections. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Hermann Einsele

Improving CAR-T in myeloma: dual-targeting approaches and resistance to T-cell exhaustion 1:35
Improving CAR-T in myeloma: dual-targeting approaches and resistance to T-cell exhaustion
Hermann Einsele • 17 Sep 2025
Ongoing trials in CAR T-cell therapy for multiple myeloma: the CARTITUDE trials and aMMbition 3:17
Ongoing trials in CAR T-cell therapy for multiple myeloma: the CARTITUDE trials and aMMbition
Hermann Einsele • 17 Sep 2025
CAR-T in multiple myeloma: optimizing bridging therapy & moving CAR-T into earlier lines of therapy 11:27
CAR-T in multiple myeloma: optimizing bridging therapy & moving CAR-T into earlier lines of therapy
Hermann Einsele • 10 Feb 2025
Novel CAR-T constructs on the horizon for multiple myeloma 1:16
Novel CAR-T constructs on the horizon for multiple myeloma
Hermann Einsele • 10 Feb 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals